Jefferies Starts Zynerba Pharmaceuticals (ZYNE) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Piper Jaffray Starts Zynerba Pharmaceuticals (ZYNE) at Overweight
August 31, 2015 6:25 AM EDTPiper Jaffray initiates coverage on Zynerba Pharmaceuticals (NASDAQ: ZYNE) with a Overweight rating and a price target of $42.00, saying the differentiated cannabinoid platform could drive near term value creation.
Analyst Charles Duncan commented, "Zynerba is developing novel transdermal formulations of the cannabinoid drug candidates... More
